Requirements: 1. Maintain the original format and structure. 2. The translation should be accurate, fluent, and natural. 3. Maintain professionalism and consistency. 4. Only return the translation result; do not add any explanations. Original Text: Jingjing Pharmaceutical’s Relabactam vs. Traditional β-Lactamase Inhibitors – Stable Structure, No Drug Resistance, Broad Enzyme Inhibition Spectrum “Relabactam” is a novel β-lactamase inhibitor with a DBO (Dibenzoxazolone) structure. Its core feature is the absence of a β-lactam ring, which requires it to be used in combination with imipenem/cilastatin to be effective. It is primarily used against infections caused by multi-drug resistant Gram-negative bacteria. Traditional β-lactamase inhibitors are mostly from the oxacillin class (such as clavulanate) or the penicillinase-sulbactam class (such as sulbactam and tazobactam), both of which contain a β-lactam ring and are commonly used in combination with penicillin and cephalosporin antibiotics for the treatment of mild to moderate infections. A multi-dimensional comparison chart of Relabactam and traditional inhibitors visually demonstrates the differences between the two in six key areas: Advantages of Jingjing Pharmaceutical’s Relabactam: 1. Chemical Structure Stability: 5 points. The non-β-lactam structure makes it less susceptible to hydrolysis by resistant enzymes, resulting in a longer half-life. 2. Drug Resistance Risk: 5 points. It has a reversible inhibition mechanism and no evidence of inducing drug resistance, making it suitable for long-term treatment in severe cases. 3. Broad Enzyme Inhibition Spectrum: 4 points. It can effectively inhibit Class A β-lactamases (including KPC carbapenemases) and Class C β-lactamases (AmpC enzymes), which traditional inhibitors do not possess. Traditional inhibitors can only inhibit some Class A enzymes (excluding carbapenemases) and have weak effects on Class C enzymes, as well as virtually no activity against Class B metalloenzymes and Class D OXA-48 enzymes. For infections caused by KPC-resistant Enterobacteriaceae (CRE), Relabactam can increase the sensitivity of imipenem from 10%-20% to 60%-80%, while traditional inhibitors are completely ineffective against such infections. 4. Clinical Application: 4 points. It covers severe cases of drug-resistant bacterial infections, filling a clinical gap left by traditional inhibitors. 5. Safety: 4 points. The side effects are similar to those of traditional inhibitors, with no additional safety risks. Advantages of Traditional Inhibitors: 1. Cost-Effectiveness: 5 points. They are inexpensive and have been used clinically for many years, with low production costs. Conclusion: Jingjing Pharmaceutical’s Relabactam has significant advantages in key areas such as combating drug-resistant bacteria and reducing the risk of drug resistance, making it suitable for the treatment of severe infections. Traditional inhibitors, on the other hand, have advantages in terms of cost and suitability for mild to moderate infections, making them more appropriate for use at the primary care level or in milder cases.